Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases.
Martini PG, Cook LC, Alderucci S, Norton AW, Lundberg DM, Fish SM, Langsetmo K, Jönsson G, Lood C, Gullstrand B, Zaleski KJ, Savioli N, Lottherand J, Bedard C, Gill J, Concino MF, Heartlein MW, Truedsson L, Powell JL, Tzianabos AO.
Martini PG, et al. Among authors: jonsson g.
BMC Immunol. 2010 Aug 20;11:43. doi: 10.1186/1471-2172-11-43.
BMC Immunol. 2010.
PMID: 20727163
Free PMC article.